凤凰网港股|AzurRx BioPharma(AZRX)宣布已与H.C.Wainwright&Co.签订承销协议。根据该协议,承销商将以每股55美分的价格向公众销售AzurRx 545.45万股普通股,该交易预计将在7月27日完成。H.C. Wainwright & Co.是此次发行的唯一簿记管理人。
该公司已授予承销商一项30天的选择权,可以在扣除承销折扣和佣金后,以公开发行价额外购买至多81.82万股普通股。AzurRx在扣除折扣、佣金和发行费用,并假设承销商未行使额外购股权利,则总收益预计为300万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.